Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UPMC REMAP: Core Protocol - Enhanced Recovery Protocols (ERP)
NCT04606264Phase 3Completed
- Start
- May 2023
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of Perphenazine, aprepitant, dimenhydrinate, ondansetron, dexamethasone and 2 more in postoperative nausea and vomiting (PONV) and postoperative pain (10 arms). Primary endpoint: 30 Day Hospital Free Days. Started May 2023; status: completed.
02
Drugs
Perphenazineaprepitantdimenhydrinateondansetrondexamethasone
03
Conditions
postoperative nausea and vomiting (PONV)postoperative pain
Beyond the preview
Go deeper on NCT04606264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04606264.